Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daito Pharmaceutical CoTSE:4577 74 Net Margin % is 8.92% as of Feb. 2026, which is 14% above its 10-year median of 7.81. GuruFocus rates TSE:4577 with a GF Score™ of 74/100 and a GF Value™ of 円1,282.65 (Fairly Valued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Daito Pharmaceutical Co ranks better than 53.08% on this metric.
Daito Pharmaceutical Co (TSE:4577) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Daito Pharmaceutical Co Net Margin % Related Terms
Daito Pharmaceutical Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Daito Pharmaceutical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daito Pharmaceutical Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daito Pharmaceutical Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Daito Pharmaceutical Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daito Pharmaceutical Co (TSE:4577) has a Net Margin % of 8.92% as of Feb. 2026. Net margin is the ratio of total net income to net sales. View historical data on Daito Pharmaceutical Co and its competitors. This is 14% above median its historical median of 7.81. Over the past decade, Daito Pharmaceutical Co's Net Margin % has ranged from 3.77 to 10.74. According to the industry distribution chart, Daito Pharmaceutical Co ranks #450 out of 959 companies in the Drug Manufacturers industry, placing it in the top 46.9%.
Is Daito Pharmaceutical Co's Net Margin % too high?
Daito Pharmaceutical Co's current Net Margin % of 8.92% is 14% above median its 10-year median of 7.81. Over the past 10 years, this metric has ranged from a low of 3.77 to a high of 10.74. The Drug Manufacturers industry median Net Margin % is 5.32. Daito Pharmaceutical Co's value of 8.92% is 67.7% above this industry median. Based on the distribution chart, Daito Pharmaceutical Co ranks #450 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daito Pharmaceutical Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daito Pharmaceutical Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Daito Pharmaceutical Co ranks #450 out of 959 companies for Net Margin %. This puts Daito Pharmaceutical Co in the upper half of its industry. The industry median Net Margin % is 5.32. Daito Pharmaceutical Co's value of 8.92% is 67.7% above this benchmark. Historically, Daito Pharmaceutical Co's own Net Margin % has ranged from 3.77 to 10.74 over the past decade. While the company's 10-year median is 7.81 vs. the industry median of 5.32, Daito Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.32, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daito Pharmaceutical Co's current Net Margin % of 8.92% is 67.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Daito Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daito Pharmaceutical Co's current Net Margin % is 8.92%, which is 14% above median its own 10-year median of 7.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daito Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daito Pharmaceutical Co (TSE:4577) is currently considered Fairly Valued. The stock's GF Value™ is 円1,282.65, compared to a current price of 円1,276.00 — trading 0.5% below its estimated fair value. The current Net Margin % is 8.92%, which is 14% above median its 10-year median of 7.81 and 67.7% above the Drug Manufacturers industry median of 5.32. Daito Pharmaceutical Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Daito Pharmaceutical Co (TSE:4577), the current Net Margin % is 8.92% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?
Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,276.00 is trading 0.5% below its estimated GF Value™ of 円1,282.65.
GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4577:
Net Margin %: 8.92% (14% above median its 10-year median of 7.81)
GF Value™: 円1,282.65 vs. price of 円1,276.00 (0.5% below fair value)
Industry Position: 67.7% above the Drug Manufacturers median (#450 of 959)
No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4577 has been successfully added to your 
